Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenz Jahn

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Bone Marrow Transplantation|January 26, 2018
Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistanceMarcel van den Brink, Markus Uhrberg, Lorenz Jahn, et al.
Blood|November 22, 2014
Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79bLorenz Jahn, Pleun Hombrink, Chopie Hassan, et al.
The Journal of Biological Chemistry|December 16, 2014
Naturally processed non-canonical HLA-A*02:01 presented peptidesChopie Hassan, Eric Chabrol, Lorenz Jahn, et al.
Oncotarget|October 25, 2016
Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodiesLorenz Jahn, Dirk M van der Steen, Renate S Hagedoorn, et al.
Oncotarget|October 1, 2016
A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transferLorenz Jahn, Renate S Hagedoorn, Dirk M van der Steen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology ApproachPleun Hombrink, Chopie Hassan, Michel G D Kester, et al.
Blood|January 6, 2017
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1Lorenz Jahn, Pleun Hombrink, Renate S Hagedoorn, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2021
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapyMiranda H Meeuwsen, Anne K Wouters, Lorenz Jahn, et al.
Immunity|February 1, 2025
Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damageAndri L Lemarquis, Anastasia I Kousa, Kimon V Argyropoulos, et al.
Nature|September 7, 2022
Novel antigen-presenting cell imparts T<sub>reg</sub>-dependent tolerance to gut microbiotaBlossom Akagbosu, Zakieh Tayyebi, Gayathri Shibu, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Bone Marrow Transplantation|January 26, 2018
Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistanceMarcel van den Brink, Markus Uhrberg, Lorenz Jahn, et al.
Blood|November 22, 2014
Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79bLorenz Jahn, Pleun Hombrink, Chopie Hassan, et al.
The Journal of Biological Chemistry|December 16, 2014
Naturally processed non-canonical HLA-A*02:01 presented peptidesChopie Hassan, Eric Chabrol, Lorenz Jahn, et al.
Oncotarget|October 25, 2016
Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodiesLorenz Jahn, Dirk M van der Steen, Renate S Hagedoorn, et al.
Oncotarget|October 1, 2016
A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transferLorenz Jahn, Renate S Hagedoorn, Dirk M van der Steen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology ApproachPleun Hombrink, Chopie Hassan, Michel G D Kester, et al.
Blood|January 6, 2017
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1Lorenz Jahn, Pleun Hombrink, Renate S Hagedoorn, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2021
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapyMiranda H Meeuwsen, Anne K Wouters, Lorenz Jahn, et al.
Immunity|February 1, 2025
Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damageAndri L Lemarquis, Anastasia I Kousa, Kimon V Argyropoulos, et al.
Nature|September 7, 2022
Novel antigen-presenting cell imparts T<sub>reg</sub>-dependent tolerance to gut microbiotaBlossom Akagbosu, Zakieh Tayyebi, Gayathri Shibu, et al.
Pageof 2